home / stock / cvrx / cvrx news

CVRX News and Press, CVRx Inc. From 03/21/23

Stock Information
Company Name: CVRx Inc.
Stock Symbol: CVRX
Market: NASDAQ
Website: cvrx.com
Menu
CVRX CVRX Quote CVRX Short CVRX News CVRX Articles CVRX Message Board
Get CVRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CVRX - Totality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patien...
CVRX - CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular d...

CVRX - CVRx: Price Response For Barostim Trial Equals Uncertainty On Equity Curve

Summary Heavy selloff following top-line data from the BeAT-HF trial, that failed to meet primary endpoint. Still, there were numerous secondary data that were positive. CVRX is subsequently submitting for label expansion for Barostim. Price needs to find equilibrium in order to...

CVRX - CVRx crashes 34% as trial for heart failure therapy fails

Medical device maker CVRx ( NASDAQ: CVRX ) lost ~34% pre-market Tuesday after announcing that its BeAT-HF post-market phase trial for FDA-authorized heart failure therapy Barostim did not reach the primary endpoint with statistical significance. Barostim is an implantable device t...
CVRX - CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular di...

CVRX - CVRx, Inc. (CVRX) Q4 2022 Earnings Call Transcript

CVRx, Inc. (CVRX) Q4 2022 Earnings Conference Call January 26, 2023 5:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants ...

CVRX - CVRx GAAP EPS of -$0.51 beats by $0.05, revenue of $7.18M beats by $0.2M

CVRx press release ( NASDAQ: CVRX ): Q4 GAAP EPS of -$0.51 beats by $0.05 . Revenue of $7.18M (+96.2% Y/Y) beats by $0.2M . Q1 2023 Outlook: The Company expects to report total revenue between $7.1 million and $7.5 million. 2023 Outlook: Total revenue betwe...
CVRX - CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its f...

CVRX - CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to rel...

CVRX - CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary ...
Previous 10 Next 10